Fuan Pharmaceutical Group Co Ltd

Fuan Pharmaceutical Group Co Ltd has a market capitalization of 4.74 billion CNY and a price-to-earnings ratio of 61.5, indicating a relatively high valuation compared to its earnings. The company's liquidity position is characterized by a current ratio of 2.32, suggesting it has sufficient short-term assets to cover its liabilities. However, the company's net cash position is negative after subtracting total debt, which may pose a liquidity risk. In terms of profitability, the company's return on equity is 1.76%, and its return on assets is 1.34%, both of which are below the typical thresholds for strong performance in the pharmaceutical industry. The gross profit margin is 35.76%, and the operating margin is 4.69%, indicating that the company is generating modest operating profits relative to its revenue. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration may increase the company's exposure to market-specific risks and reduce its ability to offset losses in one area with gains in another. Looking at the company's growth trajectory, the most recent fiscal year saw revenue of 1.74 billion CNY, with no specific growth rate provided. The company's capital expenditures were negative at -108.43 million CNY, suggesting a reduction in investment in physical assets. The company's free cash flow is 68.24 million CNY, which is relatively modest and may limit its ability to reinvest in growth opportunities. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests that the company may need to manage its cash flow carefully to avoid liquidity constraints. The company's debt-to-equity ratio is 0.19, indicating a relatively low level of leverage. Recent events and filings do not provide specific details on new product launches, regulatory changes, or significant corporate actions. The company's financial statements and analyst estimates suggest a stable but modest performance, with the last actual EPS reported at 0.06 CNY and revenue at 1.74 billion CNY.